# Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

Study · id `cardio:ct-nct01693029` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01693029](<https://clinicaltrials.gov/study/NCT01693029>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01693029

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 435 participants.

## Technical summary

Registry record NCT01693029. Randomized; quadruple masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2017-05-12.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 435 participants (enrolled count; ClinicalTrials.gov record NCT01693029, source copy `cardio:ctgov-nct01693029-2017-07-02`, retrieved 2026-10-26)
- Start date: 2012-09 (registry gives no type) (ClinicalTrials.gov record NCT01693029, source copy `cardio:ctgov-nct01693029-2017-07-02`, retrieved 2026-10-26)
- Primary completion: 2014-05 (actual) (ClinicalTrials.gov record NCT01693029, source copy `cardio:ctgov-nct01693029-2017-07-02`, retrieved 2026-10-26)
- Completion: 2015-03 (actual) (ClinicalTrials.gov record NCT01693029, source copy `cardio:ctgov-nct01693029-2017-07-02`, retrieved 2026-10-26)
- Results first posted: 2017-05-12 (ClinicalTrials.gov record NCT01693029, source copy `cardio:ctgov-nct01693029-2017-07-02`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01693029, source copy `cardio:ctgov-nct01693029-2017-07-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01693029-2017-07-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
- Acronym: ACCESS
- Condition: Anemia
- Condition: Chronic Kidney Disease (CKD)
- Intervention (Drug): HX575 epoetin alfa
- Intervention (Drug): US-licensed epoetin alfa
- Lead sponsor: Sandoz
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease (`cardio:pubmed-29084409`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7c455b6145ec4809620c32d02fd43d0e8873f72a862d4393297e50f0f4dca105
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
